The ‘Fits & Starts’ Of MAT Adoption

In my many discussions with executive teams, they often talk about their "creative" or "innovative” programming and their concerns about whether they have adopted the right innovation. One such innovation is medication assisted treatment (MAT)—the adoption of which has progressed in the market in “fits and starts.”

On the bright side, we have seen a lot of policy that is supporting MAT in recent years. A quick rundown of “available” money includes Congress’ 2018 approval of the omnibus spending bill that appropriated $3.3 billion to address the opioid and mental health crisis in fiscal year 2018 (see How . . .